1. The Results
a. Revenue
Teladoc Health’s organic revenue grew by 41% vs. 69% sequentially.
The 2nd quarter internal guide was for $495 to $505 million in total revenue.
b. Product Demand
The 2nd quarter internal guide was for 52 to 53 million U.S. paid members and 3.2 to 3.4 million total visits.
c. Profitability
Teladoc’s internal 2nd quarter adjusted EBITDA guide was for 12.1%-12.9%.
Over the first 6 months of 2021, Teladoc’s cash flow from operations margin was 3.5% vs. 6.9% in the year-ago period.
Total net loss in the quarter was $133.8 million. This includes $83 million in stock based compensation related to the Livongo Transaction, $46 million in amortization expenses related to m&a and $31 million in debt extinguishment charges. When subbing these non-recurring costs out, Teladoc earned $26.2 million in net income.
